Safety analysis of fondaparinux in pregnancy based on case report literature

WANG Yin; CAI Fengqun; KANG Fengjiao; WU Liuyun; WANG Hulin; HAN Lizhu; YIN Qinan; YANG Yong; BIAN Yuan

doi:10.6039/j.issn.1001-0408.2025.09.14

您当前的位置：

首页 >

文章列表页 >

Safety analysis of fondaparinux in pregnancy based on case report literature

更新时间：2025-09-23

- Safety analysis of fondaparinux in pregnancy based on case report literature
- ZHONGGUO YAOFANG Vol. 36, Issue 9, Pages: 1099-1104(2025)
- 作者机构：
  
  1.电子科技大学医学院，成都;610054
  2.四川省医学科学院·四川省人民医院（电子科技大学附属医院）药学部/个体化药物治疗四川省重点实验室，成都　610072
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.09.14
  CLC： R969.3;R973
- Received：25 December 2024，
  
  Revised：2025-04-21，
  
  Accepted：22 April 2025，
  
  Published：15 May 2025
- 稿件说明：
移动端阅览
王银,蔡凤群,康凤娇,等.基于病例报告文献的妊娠期使用磺达肝癸钠安全性分析 [J].中国药房,2025,36(09):1099-1104.

WANG Yin,CAI Fengqun,KANG Fengjiao,et al.Safety analysis of fondaparinux in pregnancy based on case report literature[J].ZHONGGUO YAOFANG,2025,36(09):1099-1104.
王银,蔡凤群,康凤娇,等.基于病例报告文献的妊娠期使用磺达肝癸钠安全性分析 [J].中国药房,2025,36(09):1099-1104. DOI： 10.6039/j.issn.1001-0408.2025.09.14.

WANG Yin,CAI Fengqun,KANG Fengjiao,et al.Safety analysis of fondaparinux in pregnancy based on case report literature[J].ZHONGGUO YAOFANG,2025,36(09):1099-1104. DOI： 10.6039/j.issn.1001-0408.2025.09.14.

摘要

目的

评价磺达肝癸钠在妊娠期使用的安全性，为其临床合理应用提供参考。

方法

检索中国知网、万方数据知识服务平台、PubMed、Embase和Elsevier数据库（检索时间均为从建库起至2024年12月17日），收集磺达肝癸钠在妊娠期使用的病例报告类文献，提取患者基本信息、磺达肝癸钠在妊娠期的使用情况、合并用药情况、临床表现和治疗情况等资料，进行描述性统计分析。

结果

共收集到妊娠期使用磺达肝癸钠的病例报告17篇，涉及11个国家的42例患者、47次妊娠记录。其中，20次为预防妊娠期静脉血栓栓塞（VTE）而使用磺达肝癸钠，27次因相关疾病接受磺达肝癸钠治疗。有29例次患者因VTE（家族）史而使用磺达肝癸钠；9例次患者经历复杂妊娠；35例患者有合并症/既往病史的相关记录；患者在妊娠期使用磺达肝癸钠出现的不良事件包括产后出血（7例）和不适当剂量所致的过度抗凝（1例）；在7例产后出血的病例中，有3例出血量不少于1 000 mL（包括2例合并子宫收缩乏力的患者），3例停药时间≤12 h。

结论

基于现有文献，磺达肝癸钠在妊娠期使用的安全性总体可控，主要不良事件为产后出血。磺达肝癸钠的使用剂量、停药间隔时间、合并症/既往病史和合并用药等问题可能是造成其发生不良事件的主要原因。

Abstract

OBJECTIVE

To evaluate the safety of fondaparinux in pregnancy and provide reference for its rational clinical application.

METHODS

A search was conducted in databases including CNKI， Wanfang， PubMed， Embase， and Elsevier （the search time was from the construction of the database to December 17， 2024） to collect case report literature on fondaparinux use during pregnancy. Patient demographic information， fondaparinux use during pregnancy， concomitant medications， clinical manifestations， and treatment details were extracted for descriptive statistical analysis.

RESULTS

A total of 17 case reports regarding the use of fondaparinux during pregnancy were collected， involving 42 patients from 11 countries and 47 pregnancy records. Among these， 20 cases involved the use of fondaparinux for the prevention of pregnancy-related venous thromboembolism （VTE）， while 27 cases were fondaparinux treatment due to related conditions. A total of 29 occurrences of the patients were treated with fondaparinux due to a （family） history of VTE. Nine occurrences of complicated pregnancies were reported， and 35 patients had records of comorbidities or relevant medical histories. The adverse events that occurred during pregnancy with the use of fondaparinux include postpartum hemorrhage （7 cases） and excessive anticoagulation caused by inappropriate dosage （1 case）. Among the 7 cases of postpartum hemorrhage， 3 cases had a blood loss of no less than 1 000 mL （including 2 cases with uterine atony）， 3 cases had a drug discontinuation time of ≤12 h.

CONCLUSIONS

Based on the existing literature， the safety of fondaparinux during pregnancy is generally manageable， with the main adverse event being postpartum hemorrhage. The dosage， interval between discontinuation， comorbidities/medical history， and concomitant medications of fondaparinux may be the main causes of its adverse events.

关键词

Keywords

references

MARSHALL A L . Diagnosis，treatment，and prevention of venous thromboembolism in pregnancy [J ] . Postgrad Med ， 2014 ， 126 （ 7 ）： 25 - 34 .

SARAIVA S ， MARTINS M ， SERENO S ， et al . Cutaneous hypersensitivity reaction to low molecular weight heparins in pregnancy，cross-reactivity and prednisolone treatment：a case report [J ] . Obstet Med ， 2023 ， 16 （ 4 ）： 260 - 262 .

陈奕，朱燕 . 妊娠期及产褥期静脉血栓栓塞症的诊断与治疗 [J ] . 中华妇产科杂志， 2018 ， 53 （ 9 ）： 635 - 639 .

KEAM S J ， GOA K L . Fondaparinux sodium [J ] . Drugs ， 2002 ， 62 （ 11 ）： 1673 - 1685 .

BAUERSACHS R M . Fondaparinux sodium：recent advances in the management of thrombosis [J ] . J Cardiovasc Pharmacol Ther ， 2023 ， 28 ： 10742484221145010 .

MU F X ， WANG M ， HUANG J G ， et al . Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin：a meta-analysis [J ] . Eur J Obstet Gynecol Reprod Biol ， 2023 ， 287 ： 29 - 35 .

中华医学会临床药学分会《磺达肝癸钠药学实践专家共识》编写工作组 . 磺达肝癸钠药学实践专家共识 [J ] . 医药导报， 2022 ， 41 （ 11 ）： 1571 - 1581 .

ELSAIGH E ， THACHIL J ， NASH M J ， et al . The use of fondaparinux in pregnancy [J ] . Br J Haematol ， 2015 ， 168 （ 5 ）： 762 - 764 .

SCHAPKAITZ E ， JACOBSON B F . Delayed hypersensitivity to low-molecular-weight heparin （LMWH） in pregnancy [J ] . S Afr Med J ， 2007 ， 97 （ 12 ）： 1255 - 1257 .

DEMPFLE C H . Minor transplacental passage of fondaparinux in vivo [J ] . N Engl J Med ， 2004 ， 350 （ 18 ）： 1914 - 1915 .

HARENBERG J . Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy [J ] . Thromb Res ， 2007 ， 119 （ 3 ）： 385 - 388 .

GERHARDT A ， ZOTZ R B ， STOCKSCHLAEDER M ， et al . Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous throm- boembolism and intolerance to low-molecular-weight heparins and heparinoids [J ] . Thromb Haemost ， 2007 ， 97 （ 3 ）： 496 - 497 .

CIURZYŃSKI M ， JANKOWSKI K ， PIETRZAK B ， et al . Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia [J ] . Med Sci Monit ， 2011 ， 17 （ 5 ）： CS56 - CS59 .

KNOL H M ， SCHULTINGE L ， ERWICH J M ， et al . Fondaparinux as an alternative anticoagulant therapy during pregnancy [J ] . J Thromb Haemost ， 2010 ， 8 （ 8 ）： 1876 - 1879 .

MAZZOLAI L ， HOHLFELD P ， SPERTINI F ， et al . Fondaparinux is a safe alternative in case of heparin into- lerance during pregnancy [J ] . Blood ， 2006 ， 108 （ 5 ）： 1569 - 1570 .

MAUERMANN E ， VÖKT C ， TSAKIRIS D A ， et al . Heparin-induced thrombocytopenia in pregnancy：an interdisciplinary challenge：a case report and literature review [J ] . Int J Obstet Anesth ， 2016 ， 26 ： 79 - 82 .

DINDINGER R ， MULLA B M ， STUCKY C . Case report of umbilical artery thrombosis in a patient with a history of heparin-induced thrombocytopenia [J ] . J Obstet Gynecol Neonatal Nurs ， 2023 ， 52 （ 6 ）： 501 - 508 .

WIJESIRIWARDANA A ， LEES D A R ， LUSH C . Fondaparinux as anticoagulant in a pregnant woman with heparin allergy [J ] . Blood Coagul Fibrinolysis ， 2006 ， 17 （ 2 ）： 147 - 149 .

BUONOMO A ， NUCERA E ， DE CAROLIS S ， et al . A case of heparin allergy with good tolerability to fondaparinux during pregnancy [J ] . J Investig Allergol Clin Immunol ， 2015 ， 25 （ 3 ）： 229 - 231 .

HIME N ， AUCHET T ， GUERCI P ， et al . Vaginal delivery in a parturient excessively anticoagulated with fondaparinux [J ] . Int J Obstet Anesth ， 2012 ， 21 （ 4 ）： 385 - 387 .

LOVATT C A ， CROWTHER M A . Challenging anticoagulation cases：a case of heparin-induced-thrombocytopenia in the first trimester of pregnancy [J ] . Thromb Res ， 2021 ， 207 ： 58 - 61 .

HARUTA S ， MARUTA K ， NAKAJIMA Y ， et al . Use of fondaparinux for thromboprophylaxis in an unfractionated heparin-intolerant pregnant woman with thrombotic predisposition [J ] . J Obstet Gynaecol Res ， 2017 ， 43 （ 5 ）： 943 - 945 .

EKBATANI A ， ASARO L R ， MALINOW A M . Anticoa- gulation with argatroban in a parturient with heparin-induced thrombocytopenia [J ] . Int J Obstet Anesth ， 2010 ， 19 （ 1 ）： 82 - 87 .

RENTZ J B ， HART S R ， RUSSO M . Spinal anesthesia for cesarean delivery in a patient receiving fondaparinux [J ] . Ochsner J ， 2011 ， 11 （ 1 ）： 81 - 83 .

LINNEMANN B ， SCHOLZ U ， ROTT H ， et al . Treatment of pregnancy-associated venous thromboembolism-position paper from the Working Group in Women’s Health of the Society of Thrombosis and Haemostasis （GTH） [J ] . Vasa ， 2016 ， 45 （ 2 ）： 103 - 118 .

BUTWICK A J ， CARVALHO B . Neuraxial anesthesia in obstetric patients receiving anticoagulant and antithrombotic drugs [J ] . Int J Obstet Anesth ， 2010 ， 19 （ 2 ）： 193 - 201 .

CROWTHER M A ， WARKENTIN T E . Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy：focus on new anticoagulant agents [J ] . Blood ， 2008 ， 111 （ 10 ）： 4871 - 4879 .

EUGIA US LLC . Fondaparinux sodium-fondaparinux sodium injection，solution [EB/OL ] . [ 2024-09-20 ] . https：//www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206918 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206918 .

PETERSEN S R ， BONNESEN K ， GROVE E L ， et al . Bleeding risk using non-steroidal anti-inflammatory drugs with anticoagulants after venous thromboembolism：a nationwide Danish study [J ] . Eur Heart J ， 2025 ， 46 （ 1 ）： 58 - 68 .

GARCIA D A ， BAGLIN T P ， WEITZ J I ， et al . Parenteral anticoagulants：antithrombotic therapy and prevention of thrombosis，9th Ed：American College of Chest Physicians evidence-based clinical practice guidelines [J ] . Chest ， 2012 ， 141 （ Suppl. 2 ）： e24 S-e43S.

BABIN J L ， TRAYLOR K L ， WITT D M . Laboratory monitoring of low-molecular-weight heparin and fondaparinux [J ] . Semin Thromb Hemost ， 2017 ， 43 （ 3 ）： 261 - 269 .

PAOLUCCI F ， CLAVIÉS M C ， DONAT F ， et al . Fondaparinux sodium mechanism of action：identification of specific binding to purified and human plasma-derived proteins [J ] . Clin Pharmacokinet ， 2002 ， 41 （ Suppl. 2 ）： 11 - 18 .

BAUER K A . Fondaparinux：dosing and adverse effects [EB/OL ] .（ 2023-07-25 ）[ 2024-09-15 ] . https：//www.uptodate.cn/contents/zh-Hans/fondaparinux-dosing-and-adverse-effects?search=Fondaparinux&source=search_result&selectedTitle=1%7E69&usage_type=default&display_rank=1 https://www.uptodate.cn/contents/zh-Hans/fondaparinux-dosing-and-adverse-effects?search=Fondaparinux&source=search_result&selectedTitle=1%7E69&usage_type=default&display_rank=1 .

赖宇尧，李桂珊，王志明，等 . 抗Ⅹa活性检测在抗凝药物监测中的应用 [J ] . 标记免疫分析与临床， 2020 ， 27 （ 8 ）： 1444 - 1449 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Literature analysis of tislelizumab-induced Stevens-Johnson syndrome and toxic epidermal necrolysis

Literature analysis of clinical features and risk factors of drug-induced hypofibrinogenemia

Literature analysis of aplastic anemia/pure red cell aplasia induced by pembrolizumab

Literature analysis of cardiotoxicity caused by lidocaine

Vedolizumab-associated lung toxicity：a case report and literature analysis

Related Author

JI Zhaoshuai

YANG Hua

SHEN Mingxi

HAN Rui

ZHU Man

GAO Ao

CAI Le

WEN Xiao

Related Institution

Dept. of Pharmacy， Beijing Tsinghua Changgung Hospital， School of Clinical Medicine， Tsinghua Medicine， Tsinghua University

Quality and Technology Department， No.6 Traditional Chinese Medicine Factory， Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Dept. of Pharmacy， Tsinghua University Hospital

Dept. of Pharmacy， Medical Support Center， PLA General Hospital

Dept. of Pharmacy， the First Affiliated Hospital of Soochow University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰